Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

PHASE3RecruitingINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate CancerProstatic Neoplasms
Interventions
DRUG

64Cu-SAR-bisPSMA

All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

Trial Locations (23)

6150

RECRUITING

Fiona Stanley Hospital, Murdoch

10029

RECRUITING

Mount Sinai Doctors Urology Faculty Practice, New York

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

32224

RECRUITING

Mayo Clinic- Jacksonville, Jacksonville

37209

RECRUITING

Urology Associates of Nashville, Nashville

46202

NOT_YET_RECRUITING

Indiana University School of Medicine, Indianapolis

49503

RECRUITING

BAMF Health, Grand Rapids

RECRUITING

Corewell Health, Grand Rapids

53705

RECRUITING

University of Wisconsin, Madison

55905

RECRUITING

Mayo Clinic- Rochester, Rochester

60026

RECRUITING

NorthShore University Health System, Glenview

68130

RECRUITING

XCancer Omaha LLC, Omaha

74146

RECRUITING

Urologic Specialists, Tulsa

75231

RECRUITING

Urology Clinics of North Texas, Dallas

78240

RECRUITING

The Urology Place, San Antonio

84107

RECRUITING

Intermountain Health, Murray

85054

RECRUITING

Mayo Clinic- Phoenix, Phoenix

90073

RECRUITING

Greater Los Angeles VA Medical Center, Los Angeles

97477

RECRUITING

Oregon Urology, Springfield

94305-5105

RECRUITING

Stanford University Medical Center, Stanford

75390-8896

RECRUITING

University of Texas Southwestern Medical Center, Dallas

Unknown

RECRUITING

St. Vincent's Sydney, Sydney

RECRUITING

Princess Alexandra Hospital, Woolloongabba

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY